Activating mutations on the EGFR protein, including exon 20 insertion mutations, have a role in NSCLC, but the associated structural changes resulting from the V769insASV and D770insNPG EGFR exon 20 ...
Credit: Getty Images. A PDUFA target date of November 24, 2022 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results